JP7618567B2 - 架橋型光学活性２級アミン誘導体 - Google Patents
架橋型光学活性２級アミン誘導体 Download PDFInfo
- Publication number
- JP7618567B2 JP7618567B2 JP2021549032A JP2021549032A JP7618567B2 JP 7618567 B2 JP7618567 B2 JP 7618567B2 JP 2021549032 A JP2021549032 A JP 2021549032A JP 2021549032 A JP2021549032 A JP 2021549032A JP 7618567 B2 JP7618567 B2 JP 7618567B2
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- pharma
- atom
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019176324 | 2019-09-27 | ||
| JP2019176324 | 2019-09-27 | ||
| PCT/JP2020/036219 WO2021060453A1 (ja) | 2019-09-27 | 2020-09-25 | 架橋型光学活性２級アミン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021060453A1 JPWO2021060453A1 (https=) | 2021-04-01 |
| JPWO2021060453A5 JPWO2021060453A5 (https=) | 2023-10-02 |
| JP7618567B2 true JP7618567B2 (ja) | 2025-01-21 |
Family
ID=75166233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549032A Active JP7618567B2 (ja) | 2019-09-27 | 2020-09-25 | 架橋型光学活性２級アミン誘導体 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US12559487B2 (https=) |
| JP (1) | JP7618567B2 (https=) |
| WO (1) | WO2021060453A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4263535A1 (en) | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
| US20250197392A1 (en) * | 2022-04-08 | 2025-06-19 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| AR132185A1 (es) * | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| WO2025023321A1 (en) * | 2023-07-27 | 2025-01-30 | Sumitomo Pharma Co., Ltd. | Process for preparing optically-active azabicyclo ring derivative, and intermediate for its production |
| WO2025119184A1 (zh) * | 2023-12-04 | 2025-06-12 | 首药控股(北京)股份有限公司 | 取代的多环化合物 |
| WO2026062248A1 (en) * | 2024-09-20 | 2026-03-26 | Acerta Pharma B.V. | Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017112768A1 (en) | 2015-12-22 | 2017-06-29 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018053267A1 (en) | 2016-09-16 | 2018-03-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018050686A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2019189732A1 (ja) | 2018-03-30 | 2019-10-03 | 大日本住友製薬株式会社 | 光学活性な架橋型環状２級アミン誘導体 |
| WO2020032105A1 (ja) | 2018-08-08 | 2020-02-13 | 大日本住友製薬株式会社 | 光学活性な架橋型ピペリジン誘導体 |
| WO2020045334A1 (ja) | 2018-08-27 | 2020-03-05 | 大日本住友製薬株式会社 | 光学活性なアザビシクロ環誘導体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
-
2020
- 2020-09-25 JP JP2021549032A patent/JP7618567B2/ja active Active
- 2020-09-25 WO PCT/JP2020/036219 patent/WO2021060453A1/ja not_active Ceased
- 2020-09-25 US US17/763,265 patent/US12559487B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017112768A1 (en) | 2015-12-22 | 2017-06-29 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018050686A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| WO2018053267A1 (en) | 2016-09-16 | 2018-03-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2019189732A1 (ja) | 2018-03-30 | 2019-10-03 | 大日本住友製薬株式会社 | 光学活性な架橋型環状２級アミン誘導体 |
| WO2020032105A1 (ja) | 2018-08-08 | 2020-02-13 | 大日本住友製薬株式会社 | 光学活性な架橋型ピペリジン誘導体 |
| WO2020045334A1 (ja) | 2018-08-27 | 2020-03-05 | 大日本住友製薬株式会社 | 光学活性なアザビシクロ環誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12559487B2 (en) | 2026-02-24 |
| US20220380365A1 (en) | 2022-12-01 |
| JPWO2021060453A1 (https=) | 2021-04-01 |
| WO2021060453A1 (ja) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7614262B2 (ja) | 光学活性なアザビシクロ環誘導体 | |
| JP7618567B2 (ja) | 架橋型光学活性２級アミン誘導体 | |
| CA3154073A1 (en) | Isoindolinone and indazole compounds for the degradation of egfr | |
| JP7352551B2 (ja) | 光学活性な架橋型ピペリジン誘導体 | |
| US10815241B2 (en) | Optically active azabicyclo ring derivative | |
| JP7454520B2 (ja) | 光学活性なアザビシクロ環誘導体からなる医薬 | |
| JP2023075288A (ja) | ジヒドロクロメン誘導体 | |
| JP7287929B2 (ja) | ジヒドロクロメン誘導体を含有する医薬 | |
| HK40053381A (en) | Optically active bridged piperidine derivative | |
| HK40053381B (en) | Optically active bridged piperidine derivative | |
| HK40055661A (en) | Optically active azabicyclic derivative | |
| EA041780B1 (ru) | Оптически активное азабициклическое производное |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230922 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240909 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241224 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7618567 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |